MIZOLLEN TABLETS 10 MG

국가: 이스라엘

언어: 영어

출처: Ministry of Health

지금 구매하세요

환자 정보 전단 환자 정보 전단 (PIL)
08-06-2023
제품 특성 요약 제품 특성 요약 (SPC)
13-11-2022
공공 평가 보고서 공공 평가 보고서 (PAR)
18-06-2019

유효 성분:

MIZOLASTINE

제공처:

PHARMA SHALOM

ATC 코드:

R06AX25

약제 형태:

FILM COATED TABLETS

구성:

MIZOLASTINE 10 MG

관리 경로:

PER OS

처방전 유형:

Required

Manufactured by:

SANOFI WINTHROP INDUSTRIE, FRANCE

치료 그룹:

MIZOLASTINE

치료 영역:

MIZOLASTINE

치료 징후:

Symptomatic treatment of seasonal allergic rhinoconjuctivitis (hay fever), perennial allergic rhino-conjuctivitis and urticaria.

승인 날짜:

2014-06-30

환자 정보 전단

                                PATIENT PACKAGE INSERT IN ACCORDANCE WITH THE PHARMACISTS’
REGULATIONS (PREPARATIONS) - 1986
The medicine is dispensed with a doctor’s prescription only
MIZOLLEN TABLETS 10 MG
FILM-COATED TABLETS
ACTIVE INGREDIENT: Mizolastine 10 mg.
Inactive ingredients: See Section 6.
READ THIS LEAFLET CAREFULLY IN ITS ENTIRETY BEFORE USING THE MEDICINE.
Keep this leaflet as you may need to read it again.
This leaflet contains concise information about the medicine.
If you have further questions, refer to the doctor or pharmacist.
This medicine has been prescribed for you. Do not pass it on to
others. It may harm them even if
it seems to you that their medical condition is similar.
This medicine is intended for adults and children above the age of 12.
1. WHAT IS THE MEDICINE INTENDED FOR?
Mizollen is intended for treatment of symptoms of:
•
Runny nose and conjunctivitis due to seasonal allergy (hay fever).
•
Runny nose and conjunctivitis due to a chronic allergy.
•
Urticaria (an itchy skin rash).
THERAPEUTIC GROUP: ANTIHISTAMINE.
2. BEFORE USING THE MEDICINE DO NOT USE THE MEDICINE IF:
•
You are sensitive (allergic) to the active ingredient mizolastine or
to any other
ingredient of the medicine (see Section 6).
•
You are taking a macrolide antibiotic, such as erythromycin,
clarithromycin,
azithromycin.
•
You are taking an imidazole antifungal preparation, such as
ketoconazole,
fluconazole, itraconazole.
•
You suffer from liver problems.
•
You suffer from heart problems.
•
You have a history of irregular heartbeat or a slow heart rate.
•
Your ECG (electrical recording of cardiac activity) test results are
abnormal.
•
You are being treated with medicines for heart rhythm disorders.
•
You suffer from electrolyte imbalance, particularly a low blood level
of potassium
(hypokalaemia).
SPECIAL WARNINGS REGARDING USE OF THE MEDICINE:
IN THE ELDERLY - Mizollen can make some people feel drowsy and cause a
fast heartbeat or heart
rhythm disturbances. These effects are more common in the elderly.
TESTS AND FOLLO
                                
                                전체 문서 읽기
                                
                            

제품 특성 요약

                                1
MIZOLLEN TABLETS
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
MIZOLLEN TABLETS 10 MG, film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Mizolastine 10mg per tablet.
Excipients with known effect:
Lactose monohydrate (125mg/tablet)
Hydrogenated castor oil (25mg/tablet)
Propylene glycol (0.45mg/tablet)
For the full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Modified-release tablet.
Oblong, white tablets with a scored line on one side and a mark "MZI
10" on the reverse side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Mizolastine is a long acting H1- antihistamine indicated for the
symptomatic treatment of seasonal allergic
rhinoconjunctivitis (hay fever), perennial allergic
rhinoconjunctivitis and urticaria.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Adults, including the elderly, and children 12 years of age and over:
The recommended daily dose is one 10mg tablet
4.3
CONTRAINDICATIONS
−
Hypersensitivity to the active substance or to any of the excipients
listed in section 6.1.
−
Concomitant administration with macrolide antibiotics or systemic
imidazole antifungals.
−
Significantly impaired hepatic function.
−
Clinically significant cardiac disease or a history of symptomatic
arrhythmias.
−
Patients
with
known
or
suspected
QT
prolongation
or
with
electrolyte
imbalance,
in
particular
hypokalaemia.
−
Clinically significant bradycardia.
−
Medicinal products known to prolong the QT interval, such as Class I
and III anti-arrhythmics.
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Mizolastine has a weak potential to prolong the QT interval in a few
individuals. The degree of prolongation is
modest and has not been associated with cardiac arrhythmias.
The elderly may be particularly susceptible to the sedative effects of
mizolastine and the potential effects of
the medicinal product on cardiac repolarisation.
2
Due to the presence of lactose, patients with rare
hereditary problems of galactose intolerance, total lactase
deficiency or glucose-galacto
                                
                                전체 문서 읽기
                                
                            

다른 언어로 된 문서

환자 정보 전단 환자 정보 전단 아랍어 08-06-2023
환자 정보 전단 환자 정보 전단 히브리어 13-11-2022

이 제품과 관련된 검색 알림